Conference Coverage

DECLARE-TIMI58 shows improved kidney function with dapagliflozin

Publish date: July 22, 2019

 

REPORTING FROM ADA 2019

Pages

Recommended Reading

The costs and benefits of SGLT2 inhibitors & GLP-1 RAs
Clinician Reviews
VOC-sniffing necklace may support early detection of hypoglycemia
Clinician Reviews
Mortality caused by chronic liver disease in setting of diabetes continues to rise
Clinician Reviews
Metformin linked to lower dementia risk in black patients
Clinician Reviews
Using Obamacare authority, Trump aims to shift dialysis care to patients’ homes
Clinician Reviews
Low-fat dairy associated with decreased risk of type 2 diabetes
Clinician Reviews
BMI screening trigger for type 2 diabetes is unreliable for at-risk black, Hispanic adults
Clinician Reviews
CARMELINA confirms linagliptin’s renal, CV safety, but it’s still third-line for type 2 diabetes
Clinician Reviews
FDA declines dapagliflozin indication as adjunct for type 1 diabetes
Clinician Reviews
Plant-based foods could keep type 2 diabetes at bay
Clinician Reviews